Search

everythinglearnresearchcommunity

for

Search:↓

Patients with alopecia areata face challenges accessing Janus kinase inhibitors, but some see positive results.

Baricitinib helped most teenagers with severe hair loss regrow hair and had mild side effects.

Coinheritance of BRCA2 and CYLD genes may lead to new treatment options for certain cancers.

Baricitinib helps long-term hair regrowth in severe alopecia areata patients.

A 14-year-old girl with severe hair loss regrew her hair using upadacitinib.

Baricitinib helps keep hair, eyebrows, and eyelashes regrown for 3 years in most people with severe hair loss.

Disitamab vedotin and gemcitabine effectively treated bladder cancer without major side effects.

Erlotinib may cause scarring hair loss.

Misdiagnosis led to unnecessary treatment due to a genetic mutation affecting thyroid hormone resistance.

Sintilimab treatment caused hair loss but led to complete tumor remission.

The rash resolved after stopping ponatinib.

A man developed oral hairy leukoplakia while on baricitinib, a medication for alopecia and arthritis, and doctors should watch for such side effects.

Most patients with alopecia areata see significant hair regrowth within 93 days of starting ritlecitinib treatment.

Oral JAK inhibitors effectively treat alopecia areata and are generally well-tolerated.

Patients on dabrafenib and trametinib for melanoma often experience skin side effects.

Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.

A JAK inhibitor improved both severe hair loss and chronic skin disease in one patient.

Biological therapy boosts the immune system to effectively fight melanoma.

Tofacitinib, a JAK inhibitor, improved hair regrowth in most patients with severe alopecia areata and had minimal side effects.

Baricitinib may not always prevent relapse in alopecia areata.

Erlotinib can cause unexpected side effects like eyelash growth and scarring.

Skin side effects from EGFR inhibitor cancer treatment can be managed effectively, often without stopping the medication.

Breast cancer patients taking CDK4/6 inhibitors are more likely to experience fatigue, hair loss, and mouth sores.

Tofacitinib effectively treated severe hair loss in a patient who didn't respond to other treatments.

EGFR-TKIs can cause significant skin, nail, and organ side effects.

A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.

Baricitinib significantly regrows hair in teens with severe alopecia areata.

Oral baricitinib and ruxolitinib are effective and safe for treating alopecia areata.

Upadacitinib may effectively treat alopecia areata without side effects.